Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Panbela Therapeutics Inc PBLA

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to... see more

OTCQB:PBLA - Post Discussion

Panbela Therapeutics Inc > PBLA ....R u still watching?????????
View:
Post by Iseneschal on Jan 26, 2024 12:25pm

PBLA ....R u still watching?????????

$4.50 now
Comment by Iseneschal on Jan 26, 2024 12:29pm
Mr. M is moving it up and increasing the volume....not huge but it is increasing. Maybe it's all the FOMO's .... LoL Wait for the big push......might even be after the close during AH....just so the Retail Traders are eleminated. Cheers !
Comment by Iseneschal on Jan 26, 2024 12:53pm
Sold all PBLA into the strength I like to leave some profit for the next guy....Good Luck to all
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities